Romosozumab: A Review in Postmenopausal Osteoporosis

Area of Science:

• Orthopedics
• Endocrinology
• Pharmacology

Background:

• Osteoporosis is a major health concern, particularly in postmenopausal women, leading to increased fracture risk.
• Sclerostin plays a key role in regulating bone formation and resorption.
• Current treatments for osteoporosis have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy and safety of romosozumab in treating postmenopausal osteoporosis.
• To assess the impact of romosozumab on bone mineral density and fracture risk.
• To compare romosozumab with placebo and other osteoporosis medications.

Main Methods:

• Pivotal phase III trials (FRAME and ARCH) involving postmenopausal women with osteoporosis.
• Administration of subcutaneous romosozumab (210 mg once-monthly) for 12 months.
• Subsequent transition to denosumab or alendronate for 12-24 months, with comparative analyses against placebo and alendronate-only groups.

Main Results:

• Romosozumab significantly reduced vertebral and clinical fracture risk compared to placebo and alendronate.
• Significant increases in bone mineral density (BMD) were observed with romosozumab versus placebo, alendronate, and teriparatide.
• Sustained BMD benefits were noted 12-24 months after transitioning to denosumab or alendronate.

Conclusions:

• Romosozumab is an effective treatment for severe postmenopausal osteoporosis, significantly improving BMD and reducing fracture risk.
• The benefits of romosozumab on BMD are maintained after switching to antiresorptive agents.
• Romosozumab offers a valuable new therapeutic option for postmenopausal women at high risk of fracture or those unresponsive to other treatments.